Interview 12 Jul 2022 Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets Advances in the AI-powered simulation of proteins are making it easier than ever to discover new drugs. Neil Torbett, CEO of PhoreMost, outlines how the firm’s protein screening technology overcomes current limitations of protein structure predictions, with big applications in the emerging field of protein degradation. Proteins are a critical component to a cell’s activities, […] July 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Cancer therapeutics company’s double win with $25M funding, and appointment of new board member An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Jul 2022Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb This week’s guests are: Helen Zha, assistant professor of chemical and biological engineering and a member of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute; Versameb CEO Klaas Zuideveld; and Aamir Ehsan, CEO and medical director of CorePath and Celina Villa, medical director of Biopharma Division. Versameb gives presentation during World […] July 8, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 World’s first research project for an early detection, multi-cancer screening test launched in Singapore A project for the discovery and validation of new combinations of biomarkers that can detect multi-cancer early has been launched in Singapore. Biotechnology company, MiRXES Ptr Ltd, announced this week the signing of a memorandum of understanding signaling the launch of Project CADENCE (Cancer Detected Early caN be CurEd). It is the world’s first large-scale […] July 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Destiny Pharma announces start of new oral mucositis research program Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year. Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. The research study will be […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 AstraZeneca adds to its treatments for blood cancer with $100M deal AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […] July 5, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 Nanoparticle can kill cancer cells and aid muscle relaxation A nanoparticle that is both a nanoheater and a nanothermometer at the same time has been developed by researchers at a Japanese university. The university said this is a significant development that not only aids muscle relaxation, but it can also kill cancer cells. Satoshi Arai and colleagues at Kanazawa University have successfully showed that […] July 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB. Ambrosia and Dionymer winners at 2022 TWB Start-Up Day TWB, which sets up industrial biotechnology R&D projects and designer of innovative and sustainable solutions, announces the […] July 1, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Companies unite to bolster diagnostics for cancer and liver disease Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […] June 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Breast cancer drug recommended for approval A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of disease progression or even death by 72%, has been recommended for approval in the European Union (EU). The drug containing trastuzumab deruxtecan is specifically engineered for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Trinity, St. James’s and Legend Biotech collaborating on solid tumors Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors. CAR T-cell therapies are customized for each individual patient. […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email